EUVIMEDEUVIMED entdecken
Crossref

Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy

Nehna Abdul Majeed, Ahmad Samer Alawad, Kin Seng Liem, Varun Takyar, Harvey Alter, Jordan J Feld, Harry L A Janssen, Marc G Ghany iD

Digestive Diseases and Sciences · 2023

DOI: 10.1007/s10620-023-07916-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2023. Verfasst von Nehna Abdul Majeed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis B, Hepatitis C, Hepatitis B, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Hepatitis B virus (HBV) reactivation has been reported in patients co-infected with hepatitis C virus (HCV) during direct acting antiviral (DAA) therapy, leading the United States Food and Drug Administration (U.S. FDA) to issue a black box warning on all DAA drug labels recommending monitoring for HBV reactivation. We conducted a comprehensive evaluation to assess the rate of HBV reactivation among patients with chronic hepatitis C (CHC) during DAA therapy. METHODS: Patients with CHC and recovered HBV infection (hepatitis B surface antigen negative (HBsAg)/anti-hepatitis B core positive), treated with DAAs were included if stored sera were available. Samples were tested for HBV DNA, HBsAg, and ALT. HBV reactivation was considered if (1) HBV DNA was undetectable pre-DAA therapy and became detectable post-therapy, or (2) HBV DNA was detectable pre-treatment, but not quantifiable (< 20 IU/mL) and became quantifiable post-treatment. RESULT: 79 patients with median age of 62 years were included. 68% were male and Caucasian. Various DAA regimens were administered for 12-24 weeks. Reactivation occurred in 8/79 (10%) of patients and occurred more frequently in men compared to women: 6 during treatment and 2 after treatment. Neither an ALT flare nor HBsAg seroreversion were observed. Detectable HBV DNA was transient in 5/8 and could not be determined in 3/8 but ALT flares were not observed in follow-up of these patients. CONCLUSION: The risk of HBV reactivation was low in CHC patients with resolved HBV during DAA therapy. Our data support testing for HBV DNA only in selected patients with ALT flares or failure of ALT normalization during DAA treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicHepatitis BHepatitis CHepatitis B, ChronicHumansMaleFemaleMiddle AgedAntiviral AgentsHepatitis B Surface AntigensDNA, ViralHepatitis B virusVirus Activation

Stichwörter der Autor:innen

ALT flareDirect acting antiviralsHBV DNA monitoringHepatitis B reactivationResolved Hepatitis B

Substanzen

Antiviral AgentsHepatitis B Surface AntigensDNA, Viral

Autor:innen und Institutionen

  • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, Canada.
  • The Toronto Viral Hepatitis Care Network (VIRCAN), Toronto, Canada.
  • Department of Gastroenterology, Alta Bates Summit Medical Center, Oakland, CA, USA.
  • Transfusion Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.

ORCID-Profile: Marc G Ghany

Zitieren

APA

Majeed, N. A., Alawad, A. S., Liem, K. S., Takyar, V., Alter, H., Feld, J. J., Janssen, H. L. A., & Ghany, M. G. (2023). Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-023-07916-2

Vancouver

Majeed NA, Alawad AS, Liem KS, Takyar V, Alter H, Feld JJ, et al. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy. Digestive Diseases and Sciences. 2023. doi:10.1007/s10620-023-07916-2

BibTeX
@article{Majeed2023,
  author = {Majeed, Nehna Abdul and Alawad, Ahmad Samer and Liem, Kin Seng and Takyar, Varun and Alter, Harvey and Feld, Jordan J and Janssen, Harry L A and Ghany, Marc G},
  title = {Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy},
  journal = {Digestive Diseases and Sciences},
  year = {2023},
  doi = {10.1007/s10620-023-07916-2}
}
Kostenlos starten →